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Abstract: Background: In whole foods, polyphenols exist alongside a wide array of other potentially
bioactive phytochemicals. Yet, investigations of the effects of combinations of polyphenols with
other phytochemicals are limited. Objective: The current study investigated the effects of combining
extracts of beetroot, ginseng and sage with phenolic-rich apple, blueberry and coffee berry extracts.
Design: This randomized, double-blind, placebo-controlled crossover design investigated three
active beverages in 32 healthy adults aged 18–49 years. Each investigational beverage comprised
extracts of beetroot, ginseng and sage. Each also contained a phenolic-rich extract derived from apple
(containing 234 mg flavanols), blueberry (300 mg anthocyanins) or coffee berry (440 mg chlorogenic
acid). Cognition, mood and CBF parameters were assessed at baseline and then again at 60, 180 and
360 min post-drink. Results: Robust effects on mood and CBF were seen for the apple and coffee berry
beverages, with increased subjective energetic arousal and hemodynamic responses being observed.
Fewer effects were seen with the blueberry extract beverage. Conclusions: Either the combination of
beetroot, ginseng and sage was enhanced by the synergistic addition of the apple and coffee berry
extract (and to a lesser extent the blueberry extract) or the former two phenolic-rich extracts were
capable of evincing the robust mood and CBF effects alone.
Keywords: cerebral blood flow; near-infrared spectroscopy; polyphenols; dietary nitrate
1. Introduction
Emerging data from human intervention studies suggest that polyphenol-rich foods and beverages
may be able to deliver acute benefits to cardiovascular function [1,2] and cognitive performance [3–8].
The brain function effects of polyphenols (e.g., flavanols and anthocyanins) may well be related,
in part, to their vasodilatory properties [9,10]. Here, polyphenols are able to increase endogenous
production of the potent vasodilator nitric oxide (NO) [11,12]. However, demonstrations of concurrent
modulation of cerebral blood flow (CBF) and either cognitive function or psychological state have been
elusive [5,13,14].
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In whole foods, polyphenols are found alongside a wide range of other plant-derived bioactive
compounds and yet, to date, very little research exists on the co-administration of phytochemicals.
Where data do exist, we see that combinations of phytochemicals can reveal synergistic effects [15–17].
With regard to co-administration of polyphenols with other phytochemicals, those with similar or
complementary putative mechanisms may be of most interest. For example, in addition to their direct
effects on NO production, polyphenols may also catalyze the reduction of nitrite to NO [18]; suggesting
a potential additive effect on NO production when consuming nitrates and polyphenols in combination.
In support of this, while Kennedy et al. [14] found that CBF changes were not accompanied by improved
cognitive performance 45 min following administration of the stilbene polyphenol resveratrol (even
though this represented the Tmax of plasma metabolite levels; this being broadly in line with the Tmax of
flavanol polyphenols (e.g., epigallocatechin gallate (EGCG; 78–162 min post-dose) and phenolic acids
(36–138 min post-dose [19])), a similar methodology by the same lab, using beetroot juice (a source
of dietary nitrate and polyphenols [20]) did demonstrate both improved cognitive performance and
modulation of hemodynamic responses during post-dose task performance. This commenced 90 min
after treatment and was in conjunction with significantly increased levels of plasma nitrite [21].
Although less well explored, certain constituents of herbal extracts such as sage and ginseng
also modulate NO synthesis. This may, in part, underpin some of their observed beneficial effects
on cognition and mood in acute human intervention studies [22–25]. For example, ginsenosides Rg1
and Rb1 have been shown to induce phosphorylation of endothelial nitric oxide synthase (eNOS),
resulting in increased NO production [26]. With regard to sage, the reported beneficial effects of this
herbal extract on cognition are thought to be driven by the cholinesterase-inhibiting properties of its
terpenoid constituents; of which, 1,8-cineole may be the most potent [27]. Interestingly, 1,8-cineole has
also been shown to act as a vasorelaxant; which may be driven by its actions on NO production [28].
Neither sage nor ginseng can boast a great deal of pharmacokinetic information and only a very small
proportion of this is derived from human participants following oral consumption. Nevertheless, two
small trials demonstrate that 1,8-cineole (sage) and 20(R)-ginsenoside Rg3 (metabolite of ginseng) can
achieve a Tmax of ~45 and 40 min post-oral consumption of 6.4 g sage brewed into a tea and 3.2 mg/kg
ginseng, respectively [29,30].
Given that polyphenols, beetroot, ginseng and sage share a putative common mechanism
relevant to brain function—namely modulation of NO synthesis—the objective of this randomized,
double-blind, crossover study was to explore the cognitive, mood and CBF effects of single doses of
three investigational drinks. Each of these contain extracts of beetroot, sage and ginseng, but with the
addition of separate phenolic-rich extracts derived from apple (rich in flavanols), blueberry (rich in
anthocyanins) and coffee berry (rich in chlorogenic acids). We hypothesize that co-administration of
these phenolics with beetroot, ginseng and sage will lead to differential effects on the behavioral and CBF
parameters. Given the diverse range of polyphenol structural groups, the separate phenolic-rich fruit
extracts were administered to investigate potential variability in efficacy of the different combinations
based on the individual phenolic profile of the extracts. The time course of assessments here is
somewhat exploratory, given the small amount of pharmacokinetic data available for all pertinent
active compounds in humans following oral administration, and is fairly broad (60, 180 and 360 min
post-dose) in order to mirror the Tmax of the predominant actives noted above and to extend the
possible window of opportunity.
2. Subjects and Methods
2.1. Study Design and Participants
The study followed a randomized, double-blind, placebo-controlled crossover design with
four study arms. It was conducted from August 2014 to March 2015 at the Brain, Performance
and Nutrition Research Centre (BPNRC), Northumbria University. Northumbria University’s
Health and Life Sciences Ethics Committee reviewed and approved all study procedures (code:
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RE-HLS-13-140414-534bda035fe3b) and the investigations were carried out following the rules of
the Declaration of Helsinki of 1975. The study was preregistered with Clinical trials.gov (reference:
NCT02202629).
A convenience sample of 32 adults aged 18 to 35 years completed the study, recruited from within
the staff and student population of Northumbria University (n = 6 males, 26 females, mean age 22.28
years (SD 4.27), with a mean BMI of 23.43 kg/m2, and a mean blood pressure of 119.42/77.03 mmHg,
n = 28 right handed). Participants declared themselves to be in good health, have normal or
corrected-to-normal vision and English as their first language. Exclusion criteria were a BMI of < 18 or
> 35 kg/m2, high blood pressure (defined as systolic > 139 mmHg or diastolic > 89 mmHg), smoking,
food allergies or insensitivities, pregnancy, breast feeding, currently taking any medication (use of
contraceptives was not excluded) or dietary supplements, sleep disturbances and/or taking sleep aid
medication, history of neurological, vascular or psychiatric illness, current diagnosis of anxiety or
depression, migraines, recent history (within 12 months) of alcohol/substance abuse, disorder of the
blood, heart disorder/history of vascular illness, respiratory disorder requiring regular medication,
Type I or II diabetes, renal disease, hepatic disease, severe disease of the gastrointestinal tract and any
health condition that would prevent the fulfilment of the study requirements. BMI and blood pressure
were measured in the laboratory; all other exclusion criteria were self-reported.
Sample size estimation was made assuming a medium effect size seen in previous similar
studies [4,14,31]. Using this estimate, the sample sizes for an entirely within-subjects design
incorporating four intervention groups with 0.5 correlation between repeated measures required
to achieve power of 0.8 at α = 0.05 varied between 28 participants (for the CDB cognitive measures)
and 20 participants (for the NIRS measurements). The sample size was therefore set at 32 participants
to allow for a full Latin square design.
2.2. Treatments
On each of the four test visits, participants received a different beverage by random allocation
according to a counterbalancing order (Latin square) generated by computer. All beverages were
administered in opaque containers by an independent third party who had no other involvement in
the study. The treatments were a placebo cherry-flavored beverage sweetened with sucralose (4%) and
three investigational products. The placebo contained no active ingredients and the cherry flavor was
selected to mask the flavor of the other ingredients. Each of the investigational products comprised the
placebo drink, plus 10 g beetroot extract (1.5% nitrate), 170 mg ginseng extract (4.5% ginsenosides) and
280 mg sage extract plus one of three polyphenol containing extracts—either 2.49 g blueberry extract
(300 mg blueberry anthocyanins), 275 mg apple extract (234 mg flavanols expressed as epicatechin
equivalents) or 1.1 g coffee berry extract (440 mg chlorogenic acid). See Table 1.
Table 1. Description of the investigational beverages. All beverages were made up to 10 fl oz.
Placebo Blueberry Apple Coffee Berry
Base 1 Base 1 Base 1 Base 1
Blueberry extract 2 Apple extract 6 Coffee berry extract 7
Beetroot extract 3 Beetroot extract 3 Beetroot extract 3
Ginseng extract 4 Ginseng extract 4 Ginseng extract 4
Sage extract 5 Sage extract 5 Sage extract 5
1 Water (95%), sucralose (4%), preservatives, and artificial flavors (1%). 2 Bluberry extract (2.49 g)—North American
blueberry extract standardized to contain a minimum of 12% blueberry anthocyanins. Supplied by Futureceuticals,
United States of America (USA). 3 Beetroot extract (10 g)—a fresh beetroot juice powder standardized for 1.5% nitrate
and 0.4% betalains. Supplied by Futureceuticals, USA. 4 Ginseng (170 mg)—ginseng extract standardized to contain
4.5% ginsenosides. 5 Sage extract (280 mg)—powdered sage extract. 6 Apple extract (275 mg)—standardized to
contain 85% polyphenols expressed as catechin equivalents [(-)-epicatechin min. 30% w/w; flavan-3-ol oligomers min.
20% w/w]. Supplied by Correscence Ltd., United Kingdom (UK). 7 Coffee berry extract (1.1 g)—an extract of powdered
whole coffee fruit standardized to contain 40% chlorogenic acids and 2% caffeine. Supplied by Futureceuticals, USA.
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2.3. Cognitive and Mood Assessment
All cognitive function tests were delivered using the Computerized Mental Performance
Assessment System (COMPASS, Northumbria University, Newcastle upon Tyne, UK). This testing
system delivers a tailor-made collection of tasks, with fully randomized parallel versions of each task
delivered at each assessment for each individual.
The cognitive assessment comprised four repetitions of the ten-minute battery of three tasks that
make up the Cognitive Demand Battery (CDB) plus mental fatigue and alertness visual analogue scale
ratings, resulting in a total of 40 min performance of cognitively demanding tasks per assessment. The
CDB comprises serial subtraction (3 s/7 s) and focused attention (rapid visual information processing
[RVIP]) tasks, described in full elsewhere [21]. This approach, inculcating high cognitive demands
for an extended period of time, has been shown to be sensitive to the effects of numerous nutritional
interventions [4,21,25,32].
Given that executive functioning has been shown to be sensitive to mental fatigue, two executive
function tasks (Stroop task, Peg and Ball) were also performed immediately after the CDB. In addition,
given the potential for flavonoids to modulate hippocampal function, an assessment of episodic
memory was incorporated into the battery of tasks and included immediate and delayed word recall,
word recognition and picture recognition. Similar selections of tasks delivered using COMPASS
have been shown to be sensitive to a number of nutritional interventions [33–36]. Further, these
tasks have been shown to activate the prefrontal cortex, the area of interest with regards to the NIRS
measurements [14,37,38]. Full descriptions of the above COMPASS tasks can be found in Supplemental
Table S1 and the CDB in Supplemental Table S2.
Mood/psychological state was assessed with two well-validated measures of mood including the
Bond–Lader visual analogue mood scales [39] and the Profile of Mood States (POMS) questionnaire [40].
The Bond–Lader mood scales comprise sixteen lines anchored at either end by antonyms (e.g.,
‘alert-drowsy’ and ‘calm-excited’). Participants indicate their current subjective position between the
antonyms on the line and ratings are scored as % along the line from left to right. Outcomes comprise
three factor analysis-derived scores: ‘Alertness’, ‘Calmness’ and ‘Contentment’. For the POMS, scores
on six dimensions are generated (tension/anxiety, anger/hostility, fatigue/inertia, depression/dejection,
confusion/bewilderment, vigor/activity), and an overall score termed ‘Total Mood Disturbance (TMD)’
can then be calculated by summing the five negative subscale scores and subtracting the vigor score.
A higher score on TMD indicates a greater degree of mood disturbance.
In order to further assess participants’ subjective response to the treatments, four in-house visual
analogue scales (presented as lines, as above) were also included: ‘How focused do you feel right
now?’, ‘How clear is your mind right now?’, ‘How productive do you feel right now?’, ‘How do you
rate your ability to solve a problem right now?’ The latter scale was anchored by the endpoints ‘very
bad’ (left-hand end) and ‘very good’ (right-hand end). The other scales had the endpoints ‘not at all’
(left-hand end) and ‘extremely’ (right-hand end).
The running order of the cognitive tasks is presented in Figure 1. The entire assessment took
60 min to complete.
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Figure 1. Cognitive and mood assessment with concurrent NIRS recording. 3 s, serial 3 subtractions;
7 s, serial 7 subtractions; RVIP, rapid visual information processing; VAS, visual analogue scales; POMS,
Profile of Mood States questionnaire.
2.4. NIRS
Hemodynamic response was monitored using a frequency domain ‘quantitative’ NIRS system
(OxiplexTS Frequency-Domain Near-Infrared Tissue Oximeter, ISS Science). This system gives absolute
measurements of the absorption of near-i frare light emitted at two distinct wavelengths, which allows
for the quantification of xygenated hemoglobin (HbO2) and deoxygenated hemoglobin (HHb) [41].
T ese values are then used to determine total hemoglobin (tHb = HbO2 + Hb) and oxygen saturation
(StO2 = HbO2/tHb × 100%). This system is ideal for quantifyi g acute changes i hemodynamic
response over an extended period, including in a chronic context, or as in the present study that
included 4 × 60 min assessments spread over 8 h.
Light was emitted at 691 and 830 nm by optical fibers attached in pairs to four prisms (8 fibers
in total) that were separated from the collector bundle by 2.0, 2.5, 3.0 or 3.5 cm. Each of the emitter
and collector bundle prisms were embedded into a flexible polyurethane resin to form a sensor with
the overall dimensions of 7.6 × 2.5 × 0.3 cm. Identical sensors were attached to the forehead above
each eye of participa ts with medical tape an secured in place with a self-adhering bandage. The
sensors were positioned so t at the bottom edge was level with the top of the participants’ eyebrows
and the middle edge touching at the midline of the forehead. Data were collected at a rate of 5 Hz.
Each pair collecte data from an area of prefrontal cortex that included the areas corresponding to the
international 10–20 system Fp1 and Fp2 EEG positions.
Given the exploratory nature of the study, several primary endpoints were identified including
cognitive function and fatigue during exten ed performance of the Cognitive Demand Battery at 1, 3
and 6 h post-consumption and long-term declarative emory at 1, 3 and 6 h post-intervention. All
other outcomes were identified as secondary endpoints.
2.5. Procedure
Participants were required to attend the laboratory on five occasions—a screening visit and four
test visi s. The cr ening visit c mprised briefing on requirements of the study and signing o the
informed consent form, review f the inclusion and exclusion criteria, self-reported health screening,
collection f d mog aphic data and training on the cognit ve and mood measu es. The fir t t st visit
was at least 48 h and less th n 28 ays after the screening isit, and each test visit was separated by
a minimum of seven days. On each o the four test visits, participants attended the laboratory at
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either 07:15 or 08:10 having abstained from all food and drink except water for 12 h, caffeine for 18 h
and alcohol for 24 h. In the 24 h prior to each of the test visits, participants were also required to
abstain from all polyphenol-containing foods including non-alcoholic wine and non-alcoholic beer,
decaffeinated tea and coffee, all fruits and vegetables or products made with fruit or vegetables, all
cocoa-containing products, liquorice, honey, herbs or herbal extracts, soybeans or soy products and
nuts. Participants were issued with a 24 h diet diary in which to document their food and beverage
intake for the pre-testing day, which also contained standardized instructions on which foods to avoid.
Upon arrival at the laboratory, participants were provided with a standard breakfast (2 × medium
slices of white toast and 15 g low-fat spreadable butter containing 36 g carbohydrate, 11 g fat, 7 g protein
and 2 g fiber; 1138 kJ/272 kcal) followed by a 30 min rest. Following this, the NIRS headband was
fitted and the participant then sat quietly for five min. Participants then completed the first ‘baseline’
cognitive assessment with continuous NIRS recording; NIRS data were not collected during completion
of the Bond–Lader mood scales, in-house VAS or POMS. The treatment drink was then consumed
within 5 min and then identical—save for the presentation of randomly generated parallel versions of
each memory task—cognitive/mood assessments with concomitant NIRS recording were completed at
60, 180 and 360 min post-dose. Participants were provided with a light, standard lunch immediately
following the 180 min post-dose assessments (cheese sandwich on white bread, vanilla yogurt and
savory cracker snacks containing 60 g carbohydrate, 24 g fat, 26 g protein and 2 g fiber; 2301 kJ/550 kcal,).
The low-polyphenol study visit meals were designed to provide minimal nourishment in the absence
of the same or similar compounds under investigation. Participants could drink water ad libitum
throughout the course of the test visits apart from when participating in the cognitive testing. Upon
completion of the study, participants received £170 honorarium or pro rata for withdrawals. Figure S2
in supplemental materials depicts the schedule of the testing session.
2.6. Statistics
2.6.1. Cognitive and Mood Assessment
Linear mixed models were used to test hypotheses using the mixed procedure in IBM SPSS
(version 22.0, IBM corp. Portsmouth, UK). Normality of the variables at each assessment was inspected,
and variables were log-transformed if skewed; a constant was added to all data for variables which
included 0 values. Means ± SD of all outcome variables are presented in Supplemental Tables S2–S4
(Online Supporting Material). For the models that included CDB outcomes as the dependent variable
(including mental fatigue and alertness), treatment, repetition of task (1 to 4) and time (60, 180, 360 min)
were entered into the model as fixed effects along with the interactions between each of these, i.e.,
treatment × repetition × time; treatment × repetition; treatment × time; repetition × time. Respective
pre-dose scores (baseline assessment) were also entered into the model as a covariate and subject
was included as a random effect with a variance components covariance structure. The best-fitting
covariance structure for the residuals across assessments was an autoregressive structure. Significant
main effects of treatment or significant interactions with treatment were analyzed further using
pairwise comparisons with Bonferroni corrections for multiple testing with placebo as the reference
category. Main and interaction effects were considered statistically significant at p < 0.05 and for
Bonferroni-adjusted post-hoc tests the p-value was set at p < 0.05. For all of the remaining cognitive
and mood outcomes models were used to fit the post-dose data using the procedure described above.
The fixed effects for these models were treatment, time, treatment x time with respective pre-dose
scores as a covariate; subject was included as a random effect.
2.6.2. NIRS Assessment
A single data point was calculated for each four (Serial 3 s, Serial 7 s) or five (RVIP) minute task
epoch by averaging all of the data points collected within the epoch. The analysis of the post-dose
cerebral blood flow parameters across the entire visit comprised fitting a linear mixed model including
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treatment, hemisphere (left/right) and epoch (11 × 4/5 min epochs during each assessment = 33 epochs)
and their interactions, i.e., treatment × hemisphere × epoch; treatment × hemisphere; treatment ×
epoch, hemisphere × epoch as fixed effects. Respective pre-dose values (baseline assessment) were
also entered into the model as a fixed effect and subject was included as a random effect with a
variance components covariance structure. The best-fitting covariance structure for the residuals across
assessments was an autoregressive structure. Significant fixed effects were analyzed further using
pairwise comparisons as above.
3. Results
Of the thirty-five participants who were randomized to receive treatment, three participants
withdrew post-randomization—one participant withdrew consent, one was lost to follow up and
one was withdrawn by the investigator due to inadequate NIRS data acquisition. All withdrawn
participants were replaced in order to achieve a final dataset comprising 32 complete participants. See
Supplemental Figure S1 (Online Supporting Material) for participant disposition diagram. For the VAS
measures (Bond–Lader mood scales, in-house VAS), blind analysis revealed that one participant did
not complete the scales according to the instructions by only using the extreme ends of the answer line.
These data were subsequently removed, therefore leaving 31 datasets for these outcome measures.
Two adverse events were reported as ‘possibly related to the treatment’ (headache, drowsiness; both
following the placebo beverage) and one was reported as ‘probably related to the treatment’ (headache
following the coffee berry extract beverage), while all the remaining adverse events (n = 9) were reported
as ‘unrelated to the treatment’. The dietary restrictions were not adhered to by two participants for one
study visit each (these two participants ate chocolate or tomatoes in the 24 h prior to their placebo and
coffee berry beverage study visits, respectively). As these study visits could not be re-scheduled, these
data were entered into the final dataset. Similarly, there were two instances where there were only six
days between study visits for the same participant and these data were entered into the final dataset.
On this note, the majority of participants completed each visit within seven days of their previous
visits (74%); the maximum time between any two study visits was 41 days.
3.1. Baseline Scores
There were no statistically significant differences between treatments at baseline for any of the
cognitive or mood measures. However, a main effect of treatment was observed at baseline for StO2
[F(3, 314.17) = 11.65, p < 0.001] and THb [F(3, 299.45) = 18.89, p < 0.001]. For both outcomes, pairwise
comparisons revealed higher concentrations in the placebo condition compared to all three active
treatments (all p < 0.001).
3.2. Cognitive and Mood Assessment
3.2.1. Cognitive Performance
Main effects of treatment were detected for total responses for serial 3 subtractions, total responses
for serial 7 subtractions, RVIP false alarms and reaction time on the word recognition task (all p < 0.05).
However, in all instances post-hoc comparisons between the investigational beverages and placebo
were not significantly different. A significant main effect of treatment was also observed for number of
errors of the delayed word recall task [ F (3, 113.48) = 3.08, p = 0.030]. Post-hoc comparisons revealed
more errors were made following the coffee berry extract beverage, compared to placebo (p = 0.014).
However, this was in the absence of any significant difference on the number of words correctly recalled.
No other main effects or interactions with treatment were observed.
3.2.2. Mood
A significant main effect of treatment was found for subjective ratings of alertness measured after
each repetition of the CDB [F(3, 230.43) = 3.18, p = 0.025]. Here, ratings of alertness were significantly
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higher following the apple extract beverage, compared to placebo (p = 0.0499). A significant main
effect of treatment was also found for subjective ratings of mental fatigue also measured after each
repetition of the CDB [F(3, 225.63) = 5.86, p = 0.001]. Ratings of mental fatigue were lower following
the apple extract (p = 0.002) and coffee berry extract (p = 0.003) beverages, compared to placebo. See
Figure 2 for VAS graph.
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Figure 2. Visual analogue scales. Alertness and mental fatigue were measured during completion of
the Cognitive Demand Battery. Values are adjusted means ± SEM derived from the linear mixed model
using untransformed data (n = 32). Treatment, repetition of task (1 to 4) and time (60, 180, 360 min) were
entered into the model as fixed effects along with the interactions between each of these, i.e., treatment
× repetition × time; treatment × repetition; treatment × time; repetition × time. Respective pre-dose
scores (baseli e assessment) were also entered into the model as a covariate and subject was included
as a random effect. Effects were calculated using log-transformed data. Post-hoc comparisons were
made between placebo and ach of the active tr atments using a Bonferroni adjustment for multiple
comparisons. *, p < 0.05 (post-hoc test against placebo).
Significant effects of treatment were found for a number of the POMS outcome measures:
anger/hostility [F(3, 109.27) = 3.61, p = 0.016], confusi n/bewilderment [F(3, 132.02) = 5.30, p = 0.002],
depression/dejection [F(3, 108.77) = 3.46, p = 0.019], fatigue/inertia [F(3, 127.09) = 6.46, p < 0.001] and
total mood disturbance [F(3, 119.06) = 5.75, p = 0.001]. Post-hoc comparisons against placebo are
sh wn in Figure 3. These revealed that anger/hostility (p = 0.042) and depressi /dejection (p = 0.013)
were reduced following the blueberry extract beverage, and anger/hostility (p = 0.009) was reduced
following the app e extrac b verag . Confusion/bewild rment (p = 0.001), fatigue/inertia (p < 0.001)
and t tal mood disturbance (p < 0.001) were all reduced following the coffee berry xtrac beverage.
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Figure 3. Profile of mood states. Values are adjusted means ± SEM derived from the linear mixed
model using untransformed data (n = 32). Treatment and time (60, 180, 360 min) and their interaction,
i.e., treatment x time were entered into the model as fixed effects. Respective pre-dose scores (baseline
assessment) were also entered into the model as a covariate and subject was included as a random
effect. Effects were calculated using log-transformed data. Post-hoc comparisons were made between
placebo and each of the active treatments using a Bonferroni adjustment for multiple comparisons. *,
p < 0.05 (post-hoc test against placebo).
3.2.3. NIRS
Total hemoglobin: A significant main effect of treatment was found for tHb [F(3, 2749.47) = 4.87,
p = 0.002], with increased concentration of tHb observed following the apple extract beverage across
all three post-dose assessments (p = 0.001), compared to placebo. In addition, a significant treatment x
hemisphere interaction was observed for tHb [F(3, 2190.16) = 7.82, p < 0.001]. Post-hoc comparisons
revealed that, compared to placebo, tHb was increased following the apple (p = 0.030) and coffee berry
(p < 0.001) extract beverages in the right hemisphere, and reduced in the left hemisphere following the
coffee berry extract beverage (p = 0.046).
Oxygen saturation: A significant main effect of treatment for StO2 was found [F(3, 2256.44) =
25.78, p < 0.001], with increased oxygen saturation being observed following the blueberry (p < 0.001),
apple (p < 0.001) and coffee berry (p = 0.001) extract beverages across all three post-dose assessments,
compared to placebo. A significant treatment x hemisphere interaction was also observed here.
Compared to placebo, StO2 was increased in the right hemisphere following the blueberry and apple
extract beverages (both p < 0.001) and increased in the left hemisphere following all of the active
beverages (all p < 0.001).
The above NIRS outcomes are represented graphically in Figure 4. There were no interactions
between treatment and either assessment or epoch on any NIRS measure.
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Figure 4. Near-infrared spectroscopy (NIRS) outcomes. Significant main effects of treatment (A. Total
Hb and C. StO2) and significant treatment x hemisphere interactions (B. Total Hb and D. StO2) were
observed for all outcomes (n = 32). Values are adjusted means ± SEM derived from the linear mixed
model. Treatment, hemisphere (left/right) and epoch (11 × 4/5 min epochs during each assessment = 33
epochs) and their interactions, i.e., treatment × hemisphere × epoch; treatment × hemisphere; treatment
× epoch, hemisphere × epoch were entered into the models as fixed effects. Respective pre-dose values
(baseline assessment) were also entered into the model as a covariate and subject was included as a
random effect. Post-hoc comparisons were made between placebo and each of the active treatments
using a Bonferroni adjustment for multiple comparisons. *, p < 0.05 (post-hoc test against placebo);
Total-Hb, total hemoglobin; StO2, oxygen saturation.
4. Discussion
The current study aimed to investigate the effect of combinations of differing phenolic-rich extracts
with other phytochemicals, in the form of beetroot, ginseng and sage, on CBF, cognitive function and
mood. The results here demonstrate that the combination of beetroot, sage, ginseng and phenolics
from different structural groups, in the form of flavanol-rich apple extract, anthocyanin-rich blueberry
extract or phenolic acid-rich coffee berry extract, did indeed lead to differential patterns of modulation
of mood and CBF parameters in healthy humans. The most striking finding was a clear and consistent
improvement in psychological state across the different mood measures following both the phenolic
acid- and flavanol-rich beverages. All three active treatments also led to increased oxygen saturation
in the frontal cortex, but only the flavanol-rich extract lead to increased CBF per se (as indexed by total
levels of hemoglobin).
If we look first at the mood effects, the phenolic acid-rich coffee berry extract beverage, in
comparison to placebo, was associated with reduced mental fatigue ratings during completion of
the CDB and reduced fatigue/inertia post-assessment. In addition, participants reported a decrease
in confusion/bewilderment and total mood disturbance. These findings might, on the surface, be
more readily attributed to the 22 mg caffeine also contained within this extract but several factors
might counterweight this argument. Firstly, while some will argue that this attenuation of fatigue
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is the result of reversing the putative effects of caffeine withdrawal caused by the imposed 18 h
caffeine abstinence prior to each testing session [42], the evidence for any contribution of withdrawal
to caffeine’s psychoactive effects is weak [43,44], particularly following the short period of abstinence
here [45]. Secondly, it should be noted in any event that the dose of caffeine here (22 mg) was below
the threshold dose (35 mg) generally believed to engender any psychoactive effects, even in overnight
abstinent participants [43]. Thirdly, a similar trial conducted at approximately the same time as this
one found that a decaffeinated coffee berry extract was also capable of attenuating perceptions of
increased fatigue and reduced alertness following similarly cognitively demanding tasks. However, it
is worth noting that while the cohort was equivalent to that reported here (N = 30, 19–47 yrs males and
females), the doses are not—being 300 and 100 mg in this latter trial.
Nevertheless, there is sufficient evidence for the alerting effects of decaffeinated chlorogenic acid
(CGA)-rich extract from other sources [46,47] to support its ability here. The latter of these studies [46]
showed an acute alerting effect (as well as improved cognitive performance) following a high CGA
decaffeinated coffee containing 5 mg caffeine that was not seen following a similar dose of pure
CGA/caffeine, suggesting that other constituents in the coffee-based drink contributed to these effects
see also [48]. Further, importantly, the effects in the current study were seen as a main effect across all
three post-dose assessments (60, 180, 360 min). Given the extended time course of effects seen here, the
similarity of findings on alertness across other studies, and the lack of such effects from other studies
assessing caffeine alone at this dose, it is unlikely that caffeine is the main active constituent underlying
the results seen here. However, it should also be noted that co-consumption of comparatively low
doses of caffeine has also been shown to increase the bioavailability of phenolic compounds [49,50]
and (along with other methylxanthines) exert a synergistic influence on the cardiovascular effects of
cocoa-flavanols [50]. As such, a similar interactive contribution to the psychological effects of coffee
berry extract seen here cannot be ruled out.
The apple extract beverage was also associated with a number of beneficial effects on mood. Two
patterns emerged from the data. Firstly, during completion of the CDB, subjective ratings of alertness
were increased and mental fatigue decreased following the apple extract beverage, compared to the
control drink. This finding is mirrored with cocoa flavanols, a class of polyphenols within the same
flavonoid family as the catechins found in the apple extract [4]. Secondly, the apple extract beverage
was associated with reduced anger/hostility; indicative of an anxiolytic effect of the apple extract
beverage. In mice, (-)epicatechin administration had a similar anxiolytic effect which was associated
with modulation of cortical monoamine oxidase-A (MAO-A) levels and hippocampal brain-derived
neurotrophic factor [51]. Whether the same mechanism underlies the current, acute effect in humans
remains to be investigated.
The beneficial psychological effects associated with the anthocyanin-rich drink included a reduction
in anger/hostility and depression/dejection on the POMS. Given that all three phenolic-rich extracts
were added to an identical combination of beetroot, sage and ginseng, the differential effects on mood
suggest one of two possibilities. The first is that the effects are driven by the individual phenolic
extracts themselves, and previous research that has administered similar compounds would support
this hypothesis [4,46,47,52,53]. The alternative is that the specific phenolic compounds contained
within each extract interacted with any one of the other extracts differently and possibly synergistically.
For example, although not fully understood, the mechanism of action of sage is thought to be due to its
ability to inhibit cholinesterase activity [24], a mechanism also posited for numerous polyphenolic
compounds. However, the mechanisms by which this occurs are dependent on the structural specificity
of the phenolic compound in question [54]. In addition, different phenolic compounds have been
shown to have differential efficacy with regards to modulation of NO metabolism following the
consumption of nitrate [18].
A limitation of the current study must be noted here— a beverage containing only the beetroot,
sage and ginseng extracts was not included as a comparator and, therefore, conclusions regarding
the underlying mechanisms of the effects seen here are difficult to draw. In future, for clarity, this
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comparator drink would be included to help partial out the potential input that actives like betalains
(beetroot) and ginsensosides (ginseng) may have had on the study outcomes. While no mood effects
have, to the best of current knowledge, been attributed to betalins in humans (aside from some very
recent effects related to perceived exertion in athletes [55]), they are certainly capable of modulating
cerebral blood flow in healthy adults [21]. A recent systematic review also highlighted the benefits of
ginseng on the circulatory/cardiovascular system (in part related to modulating blood flow), but, again,
no reported effects on mood [56], suggesting that beetroot and ginseng were unlikely to have impacted
mood here but that they were certainly capable of modulating blood flow.
In terms of CBF effects, all of the investigational beverages elicited an increase in oxygen
saturation in the frontal cortex during tasks that activate this brain region [14,21,38]. However, only the
flavanol-rich apple extract beverage resulted in increased levels of total hemoglobin—a proxy measure
of increased CBV—and may underpin the above findings on subjective alertness/fatigue, as has been
suggested in the case of cocoa flavanols [4]. The former, universal effect on oxygen saturation suggests
that a component or group of components common to all three beverages may have contributed to this
effect. As discussed above, the methodology here did not allow the exclusion of the three phenolic
extracts as potentially underlying this effect and the beetroot, sage and ginseng extracts are all likely
candidates given their known modulation of blood flow and NO synthesis [12,26–28].
The hemispheric interaction effect observed for total hemoglobin is more difficult to explain.
The most obvious suggestion is that, given the cognitive tasks utilized here are sub-served most
strongly by the left hemisphere, e.g., [57,58], the flavanol-rich apple extract intervention is merely
amplifying a natural, NO-driven increase in CBV in response to increased demand. Why the coffee
berry extract should attenuate this is most likely attributed to the small amount of caffeine (22 mg)
present in this extract. As discussed above, there is little evidence that caffeine is capable of evincing
cognitive/mood effects at this relatively low dose but nothing to indicate that it cannot still exert
physiological effects, including reducing CBV. It must be noted that the NIRS technique itself is limited
by its poor spatial resolution in comparison to other neuroimaging techniques [e.g., EEG and fMRI [59]]
and so hemispheric/regional differences in response to treatment using NIRS could be investigated
further with the addition of more channels. In addition, the presence of baseline differences indicating
initial higher concentrations of StO2 and THb in the placebo condition compared to all the three active
treatments suggests that the above findings should be interpreted with caution. Indeed, the observed
post-dose effects may have been attenuated in spite of the inclusion of baseline scores in the analysis.
It is perhaps surprising that no interpretable cognitive effects were noted given the observed
modulation of CBF parameters discussed above, especially with regard to the apple extract beverage.
The same pattern of increased CBV, in the absence of cognitive effects has been seen with other
polyphenols using the same methodology [14,31,53] and might suggest that this effect is predicated on
methodological factors. For example, the dose of catechins here (~235 mg) may have been too low, the
restrictive NIRS headgear too oppressive [37] or the CBF parameter effects too small to elicit effects in
young populations. Here, older populations, where oxygen delivery and mitochondrial function are in
decline [60], may present a more sensitive cohort to investigate.
In summary, it was hypothesized that the addition of three different structural groups of phenolics
(anthocyanins, flavanols and phenolic acids) to a botanical drink containing potentially bioactive [61–63]
beetroot, sage and ginseng would lead to differential patterns of modulation of cognitive function,
mood and CBF parameters. All three active drinks demonstrated varying degrees of modulation of
mood and CBF which suggests perhaps that the beetroot, sage and ginseng combination was amplified
by the addition of phytochemical polyphenols. It is of course equally possible that the polyphenol
extracts were solely responsible for the effects seen and this may explain the lack of overlap in the
observed effects between each beverage. In conclusion, the combination of different phytochemical
extracts may have potentially beneficial effects on brain function, but the specific synergies between
active constituent compounds remain to be explored.
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